- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01012700
Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers
March 27, 2014 updated by: Rockefeller University
A Randomized, Placebo-controlled, Phase I Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers
Vaccines induce protective immunity against numerous infectious diseases.
However, current vaccines have limited efficacy against challenging infections like tuberculosis, malaria and HIV.
Protein vaccines are safe but, typically, they induce weak T cell immunity when administered alone.
Therefore, special attention is being given to adjuvants, which are enhancers of immunity, that mature antigen presenting immunostimulatory dendritic cells (DCs).
Our goal is to study in humans the mechanism whereby synthetic adjuvants, acting on defined pattern recognition receptors (PRR), enhance T and B cell immunity.
In preclinical studies, the investigators' laboratory has found in mice that poly IC and its analog poly ICLC are superior adjuvants for T cell mediated immunity relative to other agonists for PRR.
In this study the investigators propose to study the safety and the innate immune responses to poly ICLC in multiple blood cell types, including three different subsets of DCs when administered subcutaneously or intranasally to healthy volunteers.
Poly ICLC is a stabilized double stranded RNA which has been extensively studied in humans with a favorable safety profile.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- The Rockefeller University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult males and females, as assessed by a medical history, physical exam, and laboratory tests
- Age of at least 18 years on the day of screening and no greater than 60 years at time of drug/placebo administration
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 4 weeks)
- In the opinion of the principal investigator or designee, has understood the information provided. Written informed consent needs to be given before any study-related procedures are performed
- Willing to undergo HIV testing and counseling, and receive HIV test results
- If a sexually active male, willing to use an effective method of contraception (condoms, anatomical sterility) throughout the study period and will be advised not to get his partner pregnant for 6 weeks after study drug administration
Females of child-bearing potential must agree to use one of the following methods of contraception for 2 weeks prior to date of screening evaluation through 6 weeks after study drug administration:
- Be surgically sterile Be abstinent (or willing to be)
- Use oral contraceptives, or other form of hormonal birth control including hormonal vaginal rings or transdermal patches
- Use an intra-uterine device (IUD)
- Use (by ensuring her male partner(s) uses) barrier contraception (condom) with spermicide
- Any other equivalent (as judged by the investigative team) methods of contraception
Exclusion Criteria:
- Any clinically significant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the trial physician within the last 6 months
- Confirmed HIV-1 or HIV-2 infection
- A medical history that includes any chronic medical problem that requires daily topical nasal medications, prior nasal or sinus surgery (including trans-nasal approaches of other organs such as pituitary, allergic rhinitis, chronic sinusitis, or any other nasal inflammatory disease that requires daily intranasal or oral medication)
- A medical history that includes any chronic pulmonary conditions including but not limited to asthma, chronic obstructive pulmonary disease and chronic bronchitis
- Any clinically significant acute or chronic medical conditions requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation
- Any laboratory value outside of reference range, with the exception of any non-clinically significant Grade 1 elevations of liver function tests (AST, ALT, direct/total bilirubin), CBC, as determined by the Principal Investigator or her designee
- Confirmed diagnosis of hepatitis B (surface antigen, HbsAg); hepatitis C (HCV antibodies) or active syphilis
- If female, pregnant, planning a pregnancy during the trial period or lactating
- Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days of poly ICLC administration
- Receipt of blood transfusion or blood products 6 months prior to drug administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: intranasal or IV
Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally.
A total of up to 24 volunteers will be enrolled in the study.
|
|
ACTIVE_COMPARATOR: Hiltonol (poly ICLC)
Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally.
A total of up to 24 volunteers will be enrolled in the study.
|
2 mg administered subcutaneously or intranasally to healthy volunteers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety of a single dose of 2mg of poly ICLC (Hiltonol) administered to healthy volunteers.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the innate immune responses to poly ICLC in multiple blood cell types in addition to whole PBMCs and three different subsets of dendritic cells after administration to healthy volunteers at different timepoints of administration.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (ACTUAL)
April 1, 2010
Study Completion (ACTUAL)
April 1, 2010
Study Registration Dates
First Submitted
November 11, 2009
First Submitted That Met QC Criteria
November 12, 2009
First Posted (ESTIMATE)
November 13, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
March 28, 2014
Last Update Submitted That Met QC Criteria
March 27, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MAC-0682
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Hiltonol (poly ICLC)
-
Nevada Cancer InstituteCLL TopicsTerminatedB Cell Lymphoma | T Cell LymphomaUnited States
-
Nina BhardwajOncovir, Inc.TerminatedMelanoma | Breast Cancer | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Skin | Sarcoma of the Skin | Basal Cell Cancer of the SkinUnited States
-
Patrick Ott, MDCompleted
-
Nina BhardwajNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHIV-1 Infected Adults With Chronic HIV-1 InfectionUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Stand Up To CancerRecruitingMutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerPancreatic Cancer | High Risk CancerUnited States
-
Nicholas ButowskiCelldex TherapeuticsActive, not recruitingGlioma | Malignant Glioma | Oligodendroglioma | Astrocytoma, Grade II | Glioma, Astrocytic | Oligoastrocytoma, MixedUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Incyte CorporationWithdrawnColorectal Cancer Metastatic | Pancreatic Cancer MetastaticUnited States
-
Massachusetts General HospitalAstraZeneca; OncoPep, Inc.Active, not recruitingBreast CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaOvarian Cancer Research CenterTerminatedFallopian Tube Cancer | Primary Peritoneal Cancer | Primary Ovarian CancerUnited States
-
Joshua BrodyCelldex TherapeuticsCompletedLow-Grade B-cell LymphomaUnited States